Tag: Boston Scientific
Kathleen Van Vlierberghe appointed vice president of Peripheral Interventions for Boston...
Boston Scientific today announced the appointment of Kathleen Van Vlierberghe as the new vice president for the Peripheral Interventions division in Europe, Middle East and...
Real-world registry shows sustained efficacy for Eluvia DES in the SFA
This advertorial is sponsored by Boston Scientific.
During a satellite symposium session dedicated to real cases and trial outcomes which was held at the Cardiovascular...
Boston Scientific completes acquisition of Silk Road Medical
Boston Scientific announced the close of its acquisition of Silk Road Medical, the company behind transcarotid artery revascularisation (TCAR).
"The integration of the TCAR platform into our portfolio...
Vascular News’ top 10 most popular stories of June 2024
The top 10 most-read Vascular News stories in June featured two US Food and Drug Administration (FDA) investigational device exemption (IDE) approvals, Boston Scientific's...
Boston Scientific announces agreement to acquire Silk Road Medical
Boston Scientific has announced that it has entered into a definitive agreement to acquire Silk Road Medical, a medical device company involved in producing...
REAL-PE demonstrates statistically significant lower major bleeding rates with Ekos system...
Data from the REAL-PE study were presented this week at TCT 2023 (23–26 October, San Francisco, USA) demonstrating that patients treated for pulmonary embolism...
Vascular News’ top 10 most popular stories of July 2023
July's top 10 highlights the US Food and Drug Administration's long-awaited update on paclitaxel-coated devices to treat peripheral arterial disease, an interview with Rachel...
Boston Scientific announces position on FDA update about use of paclitaxel-coated...
Following yesterday's news that the US Food and Drug Administration (FDA) has changed its stance on the use of paclitaxel-coated devices to treat peripheral...
Real-world data consistent with RCTs in highlighting the efficacy of drug-eluting...
This advertorial is sponsored by Boston Scientific.
During a recent satellite symposium, which took place at the 2022 Cardiovascular Interventional Radiological Society of Europe (CIRSE)...
Boston Scientific announces investment to acquire majority stake of Acotec Scientific
Boston Scientific has announced that it will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares...
Truveta announces collaboration with Boston Scientific to advance post-procedure patient insights...
Truveta announced a strategic collaborative agreement with Boston Scientific to improve long-term patient care and gain insights into healthcare disparities. Through this collaboration, Boston...
Boston Scientific announces agreement to purchase majority stake of M.I.Tech from...
M.I.Tech is the creator of the HANAROSTENT technology, a family of conformable, non-vascular, self-expanding metal stents, which have been distributed by Boston Scientific in...
Evidence in the SFA: DES ‘will be the standard of care’...
NOTE: This video is ONLY available to watch in selected countries and geographies
Marianne Brodmann (Medical University of Graz, Division of Angiology, Austria) talks...
Evidence in the SFA: Eluvia has a “significantly better” patency rate...
NOTE: This video is ONLY available to watch in selected countries and geographies
Gunnar Tepe (interventional radiologist, Germany) discusses the results and subsequent impact...
Evidence in the SFA: Considering the data when making decisions for...
NOTE: This video is ONLY available to watch in selected countries and geographies
Koen Deloose (vascular surgeon, Belgium) looks at the evidence needed in order...
Positive data for the EkoSonic endovascular system presented at VIVA 2021
Boston Scientific announced positive results for the EkoSonic endovascular system (EKOS system) during a late-breaking clinical trial presentation at Vascular Interventional Advances (VIVA) 2021...
Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy
Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...
One-year results show “superior” primary patency rate for Eluvia DES compared...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...
Boston Scientific announces agreement to acquire Devoro Medical
Today, Boston Scientific announced an agreement to acquire Devoro Medical, developer of the Wolf thrombectomy platform. The non-console and lytic-free Wolf technology targets and...
Nectero Medical completes US$19.5 million Series C financing
Nectero Medical Inc has announced the closing of its US$19.5 million Series C financing round, led by new investor Boston Scientific Corporation. Proceeds will support...
Vascular News’ top 10 most popular stories of August 2021
Research presented at the Society for Vascular Surgery’s Vascular Annual Meeting (SVS VAM 2021; 18–21 August, San Diego, USA and online)—including new VOYAGER PAD...
Boston Scientific initiates randomised controlled trial for the EkoSonic endovascular system
Boston Scientific has commenced enrolment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the...
Boston Scientific and BD initiate venous stent recalls
Boston Scientific and BD have both initiated recalls of venous stents. According to a US Food and Drug Administration (FDA) medical device recall notice...
Trialists’ insights on the 2-year results from the COMPARE trial
NOTE: This video is ONLY available to watch in selected countries and geographies
Sabine Steiner (Leipzig, Germany) sits down with Michael Jaff, the CMO...
Boston Scientific receives FDA approval for the Ranger DCB
Boston Scientific announced it has received US Food and Drug Administration (FDA) approval of the Ranger drug-coated balloon (DCB), developed for the treatment of...
Calls in Germany for reimbursement as analysis shows drug-eluting technology is...
Stefan Müller-Hülsbeck (Ev Luth Diakonissenanstalt zu Flensburg, Flensburg, Germany) presented attendees of the online meeting of the Cardiovascular and Interventional Radiological Society of Europe...
CMS grants additional reimbursement for the Eluvia drug-eluting vascular stent system
Boston Scientific announced that the US Centers for Medicare and Medicaid Services (CMS) granted a new technology add-on payment (NTAP) for the Eluvia drug-eluting...
VIVA 2019: Boston Scientific announces positive data for the Ranger DCB...
Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...
Michael Jaff joins Boston Scientific to drive innovation in peripheral technologies
Michael R Jaff is to be vice president, clinical affairs, innovation and technology, peripheral interventions of Boston Scientific by January 2020. In this role,...
CIRSE 2019: Hear the latest from clinical trials comparing paclitaxel technologies...
NOTE: ONLY intended for healthcare professionals outside of the USA and France.
Zoom in on a tête-à-tete between Marianne Brodmann (Graz, Austria) and Giovanni Torsello...
Only Eluvia Uses a Polymer for Controlled, Targeted Delivery of the...
Eluvia DES is the only technology that uses polymer-based drug delivery to treat Peripheral Artery Disease (PAD). Its polymer ensures that the majority of...
Hear the latest thoughts on paclitaxel from global experts: Their current...
Following the latest information presented at the Charing Cross (CX) International Symposium related to the meta-analysis of paclitaxel-coated devices (Katsanos et al), hear from a...
Positive outcomes of Eluvia drug-eluting stent in IMPERIAL sub-analyses
Boston Scientific has announced results from sub-analyses of the IMPERIAL clinical trial for the Eluvia Drug-Eluting Vascular Stent System at the 41st Charing Cross...
Medtronic and Boston Scientific stand by paclitaxel devices despite Katsanos’ critical...
Speaking to investors at the JP Morgan healthcare conference in San Francisco, executives from Medtronic and Boston Scientific said their data do not show...
Boston Scientific announces recommended offer to acquire BTG
Boston Scientific has announced it has reached an agreement on the terms of a recommended offer to acquire BTG, a company headquartered in the...
Positive outcomes for Eluvia stent in long lesion IMPERIAL sub-study
Clinical outcomes from the IMPERIAL Long Lesion Sub-study were presented at VIVA (5–8 November, Las Vegas, USA) demonstrating that the Eluvia drug-eluting vascular stent...
Eluvia outperforms Zilver PTX in IMPERIAL 12-month results
The Eluvia drug-eluting vascular stent system (Boston Scientific) shows superior primary patency compared to the Zilver PTX drug-eluting stent (Cook Medical), concludes the 12-month...
SAVAL trial of new below-the-knee drug-eluting stent begins
The first patient has been enrolled in the SAVAL pivotal trial to evaluate clinical outcomes of the SAVAL below-the-knee (BTK) drug-eluting stent system (Boston...
Boston Scientific to buy cerebral protection system company
Boston Scientific has signed an agreement to acquire Claret Medical, which developed and commercialised the Sentinel cerebral embolic protection system. The device is used...
First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...
Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...
Eluvia paclitaxel-eluting vascular stent system demonstrates promising three-year freedom from revascularisation
The three-year results from the MAJESTIC trial for Boston Scientific’s Eluvia paclitaxel-eluting vascular stent system at the Cardiovascular and Interventional Radiological Society of Europe...
Clearing the clot: New horizons in deep vein thrombosis treatment
In this supplement: --Life post-ATTRACT: The new challenge of DVT treatment --The future of DVT intervention in Europe: what needs to happen next --"With...
Positive results for Boston Scientific Ranger paclitaxel-coated PTA balloon catheter
Positive results from the RANGER SFA trial for Boston Scientific’s Ranger paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter have been presented at the 2017...
Endovenous laser therapy of saphenous vein reflux using thulium laser with...
In this clinical study the one-year results of the endovenous laser therapy (ELT) application of 1,940nm laser (Vela XL, Boston Scientific) with respect to...
Stefan Müller-Hülsbeck: The current drug-eluting stent landscape
In this interview, Stefan Müller-Hülsbeck, Diako Hospital, Flensburg, Germany, explains the implications of fresh two-year drug-eluting stent data from the MAJESTIC trial, and discusses...
Two-year MAJESTIC data show sustained positive results for Eluvia drug-eluting stent
The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery...
Veniti closes on US$25m from Boston Scientific
Veniti has closed on US$25m in Series D equity financing from Boston Scientific Corporation. The funds will allow Veniti to complete the VIRTUS trial...
Promising findings for novel drug-eluting peripheral stent
A new animal study, presented at EuroPCR (17–20 May, Paris), indicates that a novel, fluoropolymer-coated, self-expanding, paclitaxel-eluting peripheral stent (Eluvia, Boston Scientific) is associated...
